Invention Summary:
Rutgers scientists have invented a method of loading poly (ethylene glycol) hydrogels with doxycycline to treat vesicant-induced (i.e. sulfur mustard gas) ocular wounds. The effectiveness of doxycycline, an FDA approved drug in humans, was previously limited in ocular treatment due to tear washing on the eye’s surface. The new hydrogel system has increased viscosity which provides for prolonged corneal contact time and reduced drug loss from the corneal surface. The non-toxic, transparent hydrogels are easy to administer and would minimize patient discomfort.
Advantages:
Created with FDA approved human biocompatible materials; Inexpensive chemical materials; Increased drug loading efficiency; Prolonged pharmacological response; Transparent hydrogel does not blur vision.
Market Applications:
Therapeutics; Controlled Release; Drug Delivery; Gel Platform; Ocular Injury; Eye Injury; Chemical Warfare Treatment; Opthalmic Solutions.
Intellectual Property & Development Status:
PCT pending.
